Survey reveals ‘key barriers’ limiting PCSK9is prescribing
Just 6% of cardiologists are currently prescribing PCSK9is, despite 97% believing in their abilities.
Read More
Tag: PCSK9
Praulent gets FDA nod for heart attack and stroke
The approval was based on data from ODYSSEY OUTCOMES.
Read More
FDA approves heart protection label change for Repatha
US regulators have approved Amgen’s Repatha as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularisations in adults with cardiovascular disease.
Read More
Sanofi/Regeneron unveil more positive data for PCSK9 inhibitor
Sanofi and Regeneron have unveiled new data further backing the safety and efficacy of PCSK9 inhibitor Praluent in lowering cholesterol in patients with diabetes.
Read More
Pfizer pulls plug on PCSK9 inhibitor bococizumab
Pfizer is terminating its clinical development programme for investigational PCSK9 inhibitor bococizumab, which was being assessed by the firm for reducing cholesterol.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
